Rockefeller Capital Management
ALNY icon

Rockefeller Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Rockefeller Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.87M Sell
6,216
-221
-3% -$66.7K ﹤0.01% 1415
2026
Q1 		$2.13M Sell
6,437
-1,687
-21% -$574K ﹤0.01% 1272
2025
Q4 		$3.23M Buy
8,124
+3,744
+85% +$1.66M 0.01% 1042
2025
Q3 		$2M Buy
+4,380
New +$1.78M ﹤0.01% 1166
2024
Q2 		– Sell
-10,715
Closed -$1.6M – 1629
2024
Q1 		$1.6M Sell
10,715
-358
-3% -$59.7K ﹤0.01% 1101
2023
Q4 		$2.12M Sell
11,073
-2,111
-16% -$360K 0.01% 891
2023
Q3 		$2.33M Buy
+13,184
New +$2.52M 0.01% 786
2023
Q2 		– Sell
-8,339
Closed -$1.67M – 1815
2023
Q1 		$1.67M Sell
8,339
-2,332
-22% -$490K 0.01% 878
2022
Q4 		$2.53M Sell
10,671
-1,010
-9% -$215K 0.01% 676
2022
Q3 		$2.34M Sell
11,681
-6,067
-34% -$1.16M 0.01% 717
2022
Q2 		$2.59M Sell
17,748
-356,216
-95% -$50.5M 0.01% 683
2022
Q1 		$61.1M Sell
373,964
-12,296
-3% -$1.87M 0.29% 80
2021
Q4 		$65.5M Buy
386,260
+68,160
+21% +$12.7M 0.31% 74
2021
Q3 		$60.1M Sell
318,100
-79,209
-20% -$14.9M 0.32% 71
2021
Q2 		$67.3M Sell
397,309
-3,251
-0.8% -$476K 0.38% 53
2021
Q1 		$56.6M Buy
400,560
+11,815
+3% +$1.78M 0.38% 55
2020
Q4 		$50.5M Buy
388,745
+3,949
+1% +$527K 0.38% 61
2020
Q3 		$56M Sell
384,796
-699
-0.2% -$99.3K 0.52% 34
2020
Q2 		$57.1M Buy
385,495
+23,440
+6% +$3.16M 0.6% 33
2020
Q1 		$39.4M Sell
362,055
-161,094
-31% -$18.6M 0.52% 39
2019
Q4 		$60.3M Sell
523,149
-56,727
-10% -$5.66M 0.75% 30
2019
Q3 		$46.6M Buy
579,876
+91,356
+19% +$7.23M 0.63% 38
2019
Q2 		$35.4M Buy
488,520
+863
+0.2% +$66.2K 0.49% 47
2019
Q1 		$45.6M Buy
487,657
+1,108
+0.2% +$92.7K 0.65% 37
2018
Q4 		$35.5M Buy
486,549
+160,083
+49% +$12.3M 0.62% 42
2018
Q3 		$28.6M Buy
326,466
+58,355
+22% +$5.87M 0.43% 60
2018
Q2 		$26.4M Buy
268,111
+20,357
+8% +$2.02M 0.43% 65
2018
Q1 		$29.5M Buy
+247,754
New +$31.9M 0.49% 58

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rockefeller Capital Management's ALNY Position: Q2 2026 in Review

Rockefeller Capital Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 3.4% in Q2 2026, selling an estimated $66.7K and leaving 6,216 shares worth $1.87M. The position accounts for ﹤0.01% of the portfolio, ranked #1415.

Rockefeller Capital Management first reported a position in ALNY in Q1 2018 and has held it in 28 quarters since. The position peaked at $67.3M in Q2 2021. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Rockefeller Capital Management held 6,216 shares of Alnylam Pharmaceuticals worth $1.87M as of Q2 2026.
  • Rockefeller Capital Management sold 221 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $66.7K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #1415 holding.
  • Rockefeller Capital Management first reported a position in Alnylam Pharmaceuticals in Q1 2018 and has held it in 28 quarters since.
  • Rockefeller Capital Management's Alnylam Pharmaceuticals position peaked at $67.3M in Q2 2021.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.